Phase I trials are under way for Neboglamine.

Xytis signed a $40-million CRADA with the NIDA to test the hypothesis that Neboglamine can facilitate abstinence from cocaine or prevent relapse in cocaine addiction. Neboglamine has been shown to improve cognitive performance and have anxiolytic and antidepressive activity in preclinical animal models, according to the company.

The CRADA is subject to the completion of on-going multiple-dose escalating safety and tolerability studies. Xytis expects to complete this study during the second quarter of 2007. It is also subject to, the NIDA’s evaluation of the interaction of cocaine and Neboglamine in animals and humans.

Previous articleAblynx and Boehringer Ingelheim Embark on $265M Alzeimer’s Collaboration
Next articleSeattle Genetics Enhances Cancer Program with Two Transactions